Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | AKT1 | P31749 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.55 |
| ▸ | AKT2 | P31751 | 1/20 | 0.55 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360150 | 1.00 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2TSHRMAPK1HTT | |
| Hydrochloric Acid SCHEMBL1361906 | 0.99 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2TSHRMAPK1HTT | |
| Hydrochloric Acid SCHEMBL1361908 | 0.99 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2TSHRMAPK1HTT | |
| SCHEMBL5060680 | 0.93 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2TSHRMAPK1HTT | |
| SCHEMBL15809808 | 0.93 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2TSHRMAPK1HTT | |
| SCHEMBL15809807 | 0.93 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2TSHRMAPK1HTT | |
| SCHEMBL15809833 | 0.89 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2TSHRMAPK1HTT | |
| SCHEMBL15809810 | 0.89 | FAAH (0.60) | ALDH1A1SMN1; SMN2TSHRMAPK1HTT | |
| SCHEMBL15809809 | 0.89 | FAAH (0.60) | ALDH1A1SMN1; SMN2TSHRMAPK1HTT | |
| SCHEMBL15809954 | 0.88 | LMNA (0.64) | ALDH1A1SMN1; SMN2TSHRMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521715-B1 | PIPERAZINES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-06-25 | — | — | EP | disclosed |
| EP-1940814-B1 | PIPERAZINE DERIVATIVES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-1940814-B1 | PIPERAZINE DERIVATIVES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-2521715-A1 | PIPERAZINES AS ANTIMALARIAL AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-11-14 | — | — | EP | disclosed |
| US-8067419-B2 | N-[(S)-1-benzyl-2-(4-benzyl-piperazin-1-yl)-2-oxo-ethyl]-N-(4-pentyl-benzyl)-3-(4-trifluoromethyl-phenyl)-acrylamide, for example; antiprotozoa agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-29 | — | — | US | disclosed |
| US-8067419-B2 | N-[(S)-1-benzyl-2-(4-benzyl-piperazin-1-yl)-2-oxo-ethyl]-N-(4-pentyl-benzyl)-3-(4-trifluoromethyl-phenyl)-acrylamide, for example; antiprotozoa agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-29 | — | — | US | disclosed |
| US-8067419-B2 | N-[(S)-1-benzyl-2-(4-benzyl-piperazin-1-yl)-2-oxo-ethyl]-N-(4-pentyl-benzyl)-3-(4-trifluoromethyl-phenyl)-acrylamide, for example; antiprotozoa agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-29 | — | — | US | disclosed |
| WO-2011083413-A1 | PIPERAZINES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-07-14 | — | — | WO | disclosed |
| US-20080234272-A1 | Novel Piperazines as Antimalarial Agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-25 | — | — | US | disclosed |
| US-20080234272-A1 | Novel Piperazines as Antimalarial Agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-25 | — | — | US | disclosed |
| US-20080234272-A1 | Novel Piperazines as Antimalarial Agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-25 | — | — | US | disclosed |
| EP-1940814-A1 | PIPERAZINE DERIVATIVES AS ANTIMALARIAL AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007046075-A1 | PIPERAZINE DERIVATIVES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007046075-A1 | PIPERAZINE DERIVATIVES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234272-A1 | Novel Piperazines as Antimalarial Agents | ITPA, PAK5, THPO | ALDH1A1 1893/4885SMN1; SMN2 4627/4885TSHR 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.